#USA #Athens #Dalan Animal Health #Innate Immunity #Shrimp Vaccine

Dalan Animal Health Secures $3 Million to Advance Shrimp Vaccine Development

Dalan Animal Health, a groundbreaking bioscience firm, recently announced a successful funding round totaling $3 million through a SAFE (Simple Agreement for Future Equity) arrangement. This financing was supported by notable investors including Good Growth Capital and Meach Cove Capital, reflecting the increasing global recognition of Dalan's pioneering Innate Immunity Platform technology.

With this funding, Dalan is set to further develop its first-in-class shrimp vaccine, which addresses one of the critical disease challenges in the aquaculture sector. The shrimp industry is plagued by diseases like the White Spot Syndrome Virus, which leads to an annual loss of up to $4 billion. By combating these diseases effectively, Dalan's innovative vaccine promises to revolutionize health management practices in aquaculture, representing a significant milestone following the successful launch of its honeybee vaccine.

Dr. Annette Kleiser, CEO and Founder of Dalan Animal Health, expressed enthusiasm regarding the funding round, stating, "This funding represents a pivotal moment as we transition from proven success in honeybees to commercializing our shrimp vaccine. The participation of global investors like Good Growth Capital validates our commercial potential in aquaculture and showcases the broader capabilities of our Innate Immunity Platform."

As part of the investment, Harris Komishane, General Partner at Meach Cove Capital, will join Dalan’s Board of Directors as an observer. He highlighted the transformative potential of Dalan’s approach in protecting vital animal species through advanced vaccination technology, emphasizing its game-changing implications.

Advancing Vaccine Commercialization

The funding is primarily aimed at advancing the commercialization of Dalan's shrimp vaccine, marking a critical step forward for the company. Recent clinical trials have revealed promising efficacy results against major shrimp pathogens, allowing Dalan to move forward toward regulatory approval and market entry. The funds will support essential activities related to manufacturing scale-up, regulatory compliance, and development of market strategies crucial for a successful launch.

While the commercialization of the shrimp vaccine is the immediate focus, Dalan's vision includes broadening its platform across additional species, exploring novel applications in poultry and other aquaculture species. This expansion could not only facilitate comprehensive disease prevention but also diminish dependence on antibiotics in food production.

"Dalan's miraculous vaccine is proving to be transformative in bee protection, which is vital for our food sources. The shrimp vaccine targets the seafood protein sector, representing a lucrative market opportunity and showcasing that the platform technology can be applied to a multitude of species," states Maureen Stancik Boyce, PhD, Founder and Managing Partner of Good Growth Capital.

Strengthening European Operations with Research Grants

In addition to the SAFE financing, Dalan’s European subsidiary, Dalan Bio SL, has been granted €250k for a program aimed at pan-European honeybee disease surveillance, awarded by the Spanish Ministry of Science. This grant showcases a solid commitment to strengthening Dalan’s operations in Europe and underlines the growing international recognition of the company’s innovative approach to disease prevention.

Combining this grant with active global investor interest illustrates the increasing worldwide appeal of Dalan's platforms and their potential for international implementation.

About Good Growth Capital

Good Growth Capital focuses on supporting companies that are innovatively tackling major global challenges, investing in solutions that range from food security to environmental sustainability and human health.

About Meach Cove Capital

This investment firm is dedicated to supporting innovative biotechnology companies that create transformative solutions for global health and sustainability issues.

About Dalan Animal Health

Dalan Animal Health is committed to delivering transformative animal health solutions for a sustainable future. As pioneers in invertebrate vaccines, Dalan introduced the world's first USDA-approved honeybee vaccine and is now advancing a shrimp vaccine powered by its Innate Immunity Platform technology. This platform taps into conserved immune pathways to provide wide-ranging disease protection across multiple animal species. Dalan's biotech innovations have garnered numerous global accolades, including TIME's Best Inventions and Fast Company's Next Big Things in Tech.

For additional information regarding Dalan's vaccines and animal health solutions, visit www.dalan.com.

Forward-Looking Statements

This press release contains forward-looking statements concerning the commercialization of the shrimp vaccine, platform expansion, and potential market applications. These statements are based on current expectations and involve risks and uncertainties that could cause actual results to differ significantly from the projections made.